Merck on a Roll

Merck's stock price has almost recovered from its low point after Vioxx was withdrawn from the market in 2004. (Did you buy any in December, 2004 when it was at its lowest point?)

What has contributed to this reversal of fortunes?

Was it the recent Vioxx Litigation Victories? Was it the PR campaign?

Or was it something else?

For answers to these questions, plus a rare expression of gratitude and reversal of opinion from me, see today's post to Pharma Marketing Blog.

For more posts in related topic areas, see:

• Buzz/Public Relations/Image
• DTC Advertising
• Drug Companies

If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.

The collection of articles and commentary in this first Pharma Marketing News Special Supplement chronicles the emerging issues of direct-to-consumer (DTC) advertising and presents pro and con opinions from experts on how DTC needs to adapt in the post-Vioxx marketing era. Topics include: DTC Pros and Cons, Straight-Talking DTC, Communicating Risk, Biotech DTC, Print DTC, and more.

TABLE OF CONTENTS

Order and pay for Volume One now using your credit card

ONLY $29.95
PDF file delivered to you by email (usually within minutes of placing your order):

If you wish to be pay by check or credit card off-line, please use:
Printable Order Form